Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Cullen, Nicholas C. LU ; Leuzy, Antoine LU ; Palmqvist, Sebastian LU orcid ; Janelidze, Shorena LU ; Stomrud, Erik LU orcid ; Pesini, Pedro ; Sarasa, Leticia ; Allué, José Antonio ; Proctor, Nicholas K. and Zetterberg, Henrik LU , et al. (2021) In Nature Aging 1. p.114-123
Abstract

We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. A total of 573 patients with MCI from the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included in the study. The primary outcomes were longitudinal cognition and conversion to Alzheimer’s disease (AD) dementia. A model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL), but not Aβ42/Aβ40, had the best prognosis performance of all models (area under the curve = 0.88 for 4-year conversion to AD in BioFINDER, validated in ADNI), was stronger than a basic model... (More)

We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. A total of 573 patients with MCI from the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included in the study. The primary outcomes were longitudinal cognition and conversion to Alzheimer’s disease (AD) dementia. A model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL), but not Aβ42/Aβ40, had the best prognosis performance of all models (area under the curve = 0.88 for 4-year conversion to AD in BioFINDER, validated in ADNI), was stronger than a basic model of age, sex, education and baseline cognition, and performed similarly to cerebrospinal fluid biomarkers. A publicly available online tool for individualized prognosis in MCI based on our combined plasma biomarker models is introduced. Combination of plasma biomarkers may be of high value to identify individuals with MCI who will progress to AD dementia in clinical trials and in clinical practice.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Aging
volume
1
pages
10 pages
publisher
Springer
external identifiers
  • scopus:85132249048
DOI
10.1038/s43587-020-00003-5
language
English
LU publication?
yes
id
0da0906c-9ccb-413b-a705-2a29b86aefed
date added to LUP
2022-09-30 14:39:45
date last changed
2023-12-15 21:10:43
@article{0da0906c-9ccb-413b-a705-2a29b86aefed,
  abstract     = {{<p>We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. A total of 573 patients with MCI from the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included in the study. The primary outcomes were longitudinal cognition and conversion to Alzheimer’s disease (AD) dementia. A model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL), but not Aβ<sub>42</sub>/Aβ<sub>40</sub>, had the best prognosis performance of all models (area under the curve = 0.88 for 4-year conversion to AD in BioFINDER, validated in ADNI), was stronger than a basic model of age, sex, education and baseline cognition, and performed similarly to cerebrospinal fluid biomarkers. A publicly available online tool for individualized prognosis in MCI based on our combined plasma biomarker models is introduced. Combination of plasma biomarkers may be of high value to identify individuals with MCI who will progress to AD dementia in clinical trials and in clinical practice.</p>}},
  author       = {{Cullen, Nicholas C. and Leuzy, Antoine and Palmqvist, Sebastian and Janelidze, Shorena and Stomrud, Erik and Pesini, Pedro and Sarasa, Leticia and Allué, José Antonio and Proctor, Nicholas K. and Zetterberg, Henrik and Dage, Jeffrey L. and Blennow, Kaj and Mattsson-Carlgren, Niklas and Hansson, Oskar}},
  language     = {{eng}},
  pages        = {{114--123}},
  publisher    = {{Springer}},
  series       = {{Nature Aging}},
  title        = {{Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations}},
  url          = {{http://dx.doi.org/10.1038/s43587-020-00003-5}},
  doi          = {{10.1038/s43587-020-00003-5}},
  volume       = {{1}},
  year         = {{2021}},
}